ERFURT / BERLIN and STADTBERGEN, Germany – September 13th, 2021, AMP Alternative Medical Products Inc. (Frankfurt: C4TA, ISIN: CA0318961038) (CSE: XCX), a pharmaceutical supplier of medical cannabis products to German pharmacies, and WaldhausKlinik Deuringen gGmbH (“Waldhausklinik”), a non-profit acute care hospital for internal medicine in the Free State of Bavaria, announce they have entered into a research collaboration to access the efficacy and safety of medical cannabis.
Dr. Dr. Tobias Romeyke, CEO of Waldhausklinik in Augsburg, Germany, and health scientist will apply at the relevant authorities to conduct a clinical study on the therapeutic use of cannabis extracts focusing on pain therapy for patients suffering from multilocular chronic pain. Cannabis medical products containing THC and CBD will be used in a multimodal treatment setting within a retrospective controlled study. Additional case studies are also planned for the scientific evaluation.
AMP was selected by Waldhausklinik to provide European Union Good Manufacturing Practice (“EU-GMP”) medical cannabis extracts to patients in the study.
This long-term controlled study’s main goal is to evaluate the efficacy of THC and CBD in medical cannabis on pain, quality of life and pain medication consumption. Secondary objectives include accessing patients’ psychiatric and overall medical conditions, including possible side effects.
Up to forty patients will be involved in a two-year clinical study and can continue treatment if approved by their doctor at the conclusion of the study.
Over 128,000 German patients have been prescribed medical cannabis products by doctors in 2020, of which 90% of the prescriptions were covered by statutory insurance coverage according to the sixth edition of the European Cannabis Report, produced by Prohibition Partners. Rejected insurance applications are generally due to lack of supporting clinical evidence.
AMP invests in medical cannabis clinical research studies conducted in Germany to improve patient access, provide clinical evidence for doctors, lower rejection of claims and increase coverage of medical conditions that can be treated by medical cannabis by statutory insurance companies.
Dr. Dr. Tobias Romeyke, CEO of WaldhausKlinik Deuringen, commented, “It is important that Germany begins to conduct its own clinical studies into the possible medical benefits of cannabis. AMP’s complete therapeutic catalogue of medical cannabis products ensures patients in our study will have every prescription option available for their treatment.”
Dr. Stefan Feuerstein, President and Director of AMP, commented, “AMP’s investment in clinical studies into medical cannabis conducted in Germany can benefit patient’s health as doctors can have more guided information to diagnose and prescribe the appropriate prescription and statutory insurance companies may
find that medical cannabishas a role inpain and othertherapies thatpossibly lowers the patients overalltherapycosts.”
“THCandCBDuseinamultimodal treatment setting: Aretrospectivecontrolledstudy ofpatientswithmultilocularchronicpain.”TheWaldhausklinikDeuringengGmbHis a non-profitacute hospital for internalmedicineandpain therapyfounded in 1966 by doctors inAugsburg, Germany,whoseaimis toprovideindividualized patient centeredtreatments.
For moreinformation, please visitwww.waldhausklinik.de
AMP AlternativeMedical Products Inc.(formerly AMP German Cannabis Group Inc.)is a supplierofmedical cannabis and CBD cannabisproducts to German pharmacies thru its subsidiary AMP AlternativeMedical Products GmbH,with offices in Erfurtand Berlin, Germany. AMP operates in accordance with theGerman Narcotic Drug Act (BtMG) and with the regulatory requirements set by the Free State of Thuringia,ensuringproducts importedby AMP from around the world and soldinGermanymeet theEuropeanUnion-Good Manufacturing Practice (EU-GMP) standard.
The AMP Roundtable Series discusses issues aboutmedical cannabis in Germany and is available as apodcastand video. In Episode #2, “Politicsand Medical Cannabisin Germany” Dr. Wieland Schinnenburg,MdB (FDP), providesan up-to-date overview of the politicalissues and challenges facing themedicalcannabisindustry in Germany. Learn more atwww.amp-eu.de/roundtable.
To learn more aboutthe European cannabisindustry, download AMP’s sponsored report by ProhibitionPartners;https://prohibitionpartners.com/reports/the-european-cannabis-report-6th-edition/
For moreinformation, please visitwww.amp-eu.com
Alex Blodgett, CEO and Director
Valeria Bravo, Corporate and Media Communications
PD Dr. Dr. Tobias Romeyke
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accept responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements do not guarantee future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
SOURCE AMP Alternative Medical Products Inc.